FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Optimizing Screening for Cervical Cancer Among Women Living With HIV in the Dominican Republic

Not Applicable

Active, not recruiting

Conditions: Malignant Female Reproductive System Neoplasm

Interventions: Procedure: Biospecimen Collection
Other: Interview

First Posted Date: 2022-09-27

Last Posted Date: 2025-05-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 619

Registration Number: NCT05556772

Locations: 🇩🇴
Instituto Dermatológico Dominicano y Cirugía de Piel (IDCP) "Dr. Huberto Bogaert Diaz", Santo Domingo, Dominican Republic

A Video Intervention to Decrease Patient Fear of Colonoscopy After a Positive Fecal Immunochemical Test

Not Applicable

Completed

Conditions: Colorectal Carcinoma

Interventions: Other: Media Intervention
Other: Best Practice
Other: Questionnaire Administration

First Posted Date: 2022-07-14

Last Posted Date: 2024-05-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 66

Registration Number: NCT05458986

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Grade 3b Follicular Lymphoma
Refractory Grade 3b Follicular Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Lisocabtagene Maraleucel
Drug: Polymer-conjugated IL-15 Receptor Agonist NKTR-255
Procedure: X-Ray Imaging
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Lumbar Puncture
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Procedure: Biospecimen Collection
Procedure: Biopsy

First Posted Date: 2022-05-03

Last Posted Date: 2025-01-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 24

Registration Number: NCT05359211

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Tailored Screening and Smoking Cessation Program for the LGBTQ Community of Seattle

Not Applicable

Terminated

Conditions: Lung Carcinoma

Interventions: Behavioral: Patient Navigation
Other: Questionnaire Administration
Behavioral: Smoking Cessation Intervention
Procedure: Carbon Monoxide Measurement

First Posted Date: 2022-03-31

Last Posted Date: 2024-12-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT05304390

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial

Not Applicable

Terminated

Conditions: Colorectal Carcinoma

Interventions: Other: Educational Intervention
Other: Fecal Immunochemical Test
Other: Questionnaire Administration

First Posted Date: 2022-03-23

Last Posted Date: 2022-12-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 8

Registration Number: NCT05291988

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Olympic Medical Cancer Care Center, Sequim, Washington, United States

Red and Processed Meat Effects on the Metabolome and Microbiome

Not Applicable

Completed

Conditions: Red Meat
Healthy Eating Index
Meat
Controlled Feeding Trial

Interventions: Other: Randomized, cross-over controlled feeding trial testing a Healthy Eating Index 2015 (HEI-2015) diet with and without red and processed meat

First Posted Date: 2022-03-11

Last Posted Date: 2024-01-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 22

Registration Number: NCT05274906

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)

Recruiting

Conditions: Bronchiolitis Obliterans Syndrome
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Procedure: Home spirometry
Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2022-02-22

Last Posted Date: 2024-12-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 250

Registration Number: NCT05250037

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Withdrawn

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Biological: Loncastuximab Tesirine
Drug: Melphalan

First Posted Date: 2022-02-08

Last Posted Date: 2023-01-13

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT05228249

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study

Phase 1

Terminated

Conditions: Malignant Solid Neoplasm
COVID-19 Infection
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Questionnaire Administration
Biological: Sotrovimab
Procedure: Biospecimen Collection

First Posted Date: 2021-11-26

Last Posted Date: 2025-02-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05135650

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Locally Advanced Cutaneous Melanoma
Locally Advanced Mucosal Melanoma
Metastatic Acral Melanoma
Metastatic Conjunctival Melanoma
Metastatic Cutaneous Melanoma
Metastatic HER2-Negative Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma
Metastatic Lung Non-Small Cell Carcinoma

Interventions: Biological: Neoantigen Peptide Vaccine
Biological: Nivolumab
Drug: Poly ICLC
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Positron Emission Tomography

First Posted Date: 2021-10-28

Last Posted Date: 2025-03-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT05098210

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy